NASDAQ:PRTK Paratek Pharmaceuticals Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Paratek Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $5.71 +0.13 (+2.33 %) (As of 09/25/2020 12:00 AM ET) Add Compare Share Today's Range$5.57Now: $5.71▼$5.8250-Day Range$4.19MA: $4.98▼$6.6952-Week Range$2.50Now: $5.71▼$6.72Volume277,952 shsAverage Volume732,016 shsMarket Capitalization$259.16 millionP/E RatioN/ADividend YieldN/ABeta1.53 ProfileAnalyst RatingsChartCompetitorsDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and cooperative research and development agreement with the U.S. Army Medical Research Institute of Infectious Diseases to study omadacycline against pathogenic agents causing infectious diseases. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingParatek Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $17.80, Paratek Pharmaceuticals has a forecasted upside of 211.7% from its current price of $5.71.Amount of Analyst CoverageParatek Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesParatek Pharmaceuticals has received 419 “outperform” votes. (Add your “outperform” vote.)Underperform VotesParatek Pharmaceuticals has received 377 “underperform” votes. (Add your “underperform” vote.)Community SentimentParatek Pharmaceuticals has received 52.64% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Paratek Pharmaceuticals and other stocks. Vote “Outperform” if you believe PRTK will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PRTK will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldParatek Pharmaceuticals does not currently pay a dividend.Dividend GrowthParatek Pharmaceuticals does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Paratek Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.30% of the stock of Paratek Pharmaceuticals is held by insiders.Percentage Held by Institutions46.77% of the stock of Paratek Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Paratek Pharmaceuticals are expected to grow in the coming year, from ($1.78) to ($0.70) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Paratek Pharmaceuticals is -1.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Paratek Pharmaceuticals is -1.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.55 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:PRTK Previous SymbolNASDAQ:TSPT CUSIP89354M10 CIK1178711 Webwww.paratekpharma.com Phone617-807-6600Debt Debt-to-Equity RatioN/A Current Ratio6.55 Quick Ratio6.03Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$16.54 million Price / Sales15.67 Cash FlowN/A Price / Cash FlowN/A Book Value($1.19) per share Price / Book-4.80Profitability EPS (Most Recent Fiscal Year)($3.93) Net Income$-128,790,000.00 Net Margins-367.05% Return on EquityN/A Return on Assets-45.88%Miscellaneous Employees101 Outstanding Shares45,387,000Market Cap$259.16 million Next Earnings Date11/10/2020 (Estimated) OptionableOptionable $5.71 +0.13 (+2.33 %) (As of 09/25/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive PRTK News and Ratings via Email Sign-up to receive the latest news and ratings for PRTK and its competitors with MarketBeat's FREE daily newsletter. Paratek Pharmaceuticals (NASDAQ:PRTK) Frequently Asked Questions How has Paratek Pharmaceuticals' stock price been impacted by COVID-19? Paratek Pharmaceuticals' stock was trading at $3.89 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, PRTK shares have increased by 46.8% and is now trading at $5.71. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Paratek Pharmaceuticals? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Paratek Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Paratek Pharmaceuticals. When is Paratek Pharmaceuticals' next earnings date? Paratek Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020. View our earnings forecast for Paratek Pharmaceuticals. How were Paratek Pharmaceuticals' earnings last quarter? Paratek Pharmaceuticals Inc (NASDAQ:PRTK) announced its quarterly earnings data on Monday, August, 10th. The specialty pharmaceutical company reported ($0.53) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.14) by $0.39. The specialty pharmaceutical company earned $9.33 million during the quarter, compared to analyst estimates of $34.34 million. View Paratek Pharmaceuticals' earnings history. What guidance has Paratek Pharmaceuticals issued on next quarter's earnings? Paratek Pharmaceuticals issued an update on its FY 2020 Pre-Market earnings guidance on Monday, August, 10th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $78-83 million, compared to the consensus revenue estimate of $81.16 million. What price target have analysts set for PRTK? 6 brokerages have issued 1 year price targets for Paratek Pharmaceuticals' shares. Their forecasts range from $6.00 to $36.00. On average, they anticipate Paratek Pharmaceuticals' stock price to reach $17.80 in the next twelve months. This suggests a possible upside of 211.7% from the stock's current price. View analysts' price targets for Paratek Pharmaceuticals. Who are some of Paratek Pharmaceuticals' key competitors? Some companies that are related to Paratek Pharmaceuticals include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Horizon Therapeutics (HZNP), Royalty Pharma (RPRX), Jazz Pharmaceuticals (JAZZ), Mylan (MYL), Perrigo (PRGO), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX) and Corcept Therapeutics (CORT). View all competitors. What other stocks do shareholders of Paratek Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Paratek Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), CBL & Associates Properties (CBL), Corbus Pharmaceuticals (CRBP), Inovio Pharmaceuticals (INO), ADMA Biologics (ADMA), Aduro BioTech (ADRO) and Energy Transfer LP Unit (ET). Who are Paratek Pharmaceuticals' key executives? Paratek Pharmaceuticals' management team includes the following people: Mr. Michael F. Bigham CPA, MBA, Exec. Chairman (Age 62, Pay $881.68k)Dr. Evan Loh, CEO & Director (Age 61, Pay $906.9k)Mr. Adam Woodrow, Pres & Chief Commercial Officer (Age 53, Pay $672.21k)Mr. William M. Haskel, Sr. VP, Gen. Counsel, Corp. Sec. & Chief Compliance Officer (Age 58, Pay $586k)Ms. Sarah Higgins, VP, Controller and Interim Principal Financial & Accounting Officer (Age 45) What is Paratek Pharmaceuticals' stock symbol? Paratek Pharmaceuticals trades on the NASDAQ under the ticker symbol "PRTK." Who are Paratek Pharmaceuticals' major shareholders? Paratek Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include General American Investors Co. Inc. (1.98%), Water Island Capital LLC (0.73%), Trellus Management Company LLC (0.70%), Charles Schwab Investment Management Inc. (0.58%), Essex Investment Management Co. LLC (0.57%) and Goldman Sachs Group Inc. (0.52%). Company insiders that own Paratek Pharmaceuticals stock include Adam Woodrow, Douglas W Pagan, Evan Loh, Jeffrey Stein, Michael Bigham, Randall B Brenner, Thomas John Dietz and William M Haskel. View institutional ownership trends for Paratek Pharmaceuticals. Which institutional investors are selling Paratek Pharmaceuticals stock? PRTK stock was sold by a variety of institutional investors in the last quarter, including ICM Asset Management Inc. WA, Nuveen Asset Management LLC, Stifel Financial Corp, Water Island Capital LLC, Highland Capital Management Fund Advisors L.P., Gamco Investors INC. ET AL, and UBS Group AG. Company insiders that have sold Paratek Pharmaceuticals company stock in the last year include Adam Woodrow, Evan Loh, Michael Bigham, Randall B Brenner, and William M Haskel. View insider buying and selling activity for Paratek Pharmaceuticals. Which institutional investors are buying Paratek Pharmaceuticals stock? PRTK stock was acquired by a variety of institutional investors in the last quarter, including Essex Investment Management Co. LLC, Trellus Management Company LLC, Telemetry Investments L.L.C., General American Investors Co. Inc., Charles Schwab Investment Management Inc., Jane Street Group LLC, SG Americas Securities LLC, and Bank of New York Mellon Corp. View insider buying and selling activity for Paratek Pharmaceuticals. How do I buy shares of Paratek Pharmaceuticals? Shares of PRTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Paratek Pharmaceuticals' stock price today? One share of PRTK stock can currently be purchased for approximately $5.71. How big of a company is Paratek Pharmaceuticals? Paratek Pharmaceuticals has a market capitalization of $259.16 million and generates $16.54 million in revenue each year. The specialty pharmaceutical company earns $-128,790,000.00 in net income (profit) each year or ($3.93) on an earnings per share basis. Paratek Pharmaceuticals employs 101 workers across the globe. What is Paratek Pharmaceuticals' official website? The official website for Paratek Pharmaceuticals is www.paratekpharma.com. How can I contact Paratek Pharmaceuticals? Paratek Pharmaceuticals' mailing address is 75 PARK PLAZA, BOSTON MA, 02116. The specialty pharmaceutical company can be reached via phone at 617-807-6600 or via email at [email protected] This page was last updated on 9/26/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
